DFS showed consistent numerical trends but lacked significant interaction.<h4>Conclusion</h4>NACT provided a survival advantage in this real-world HR+/HER2- cohort, with benefits primarily concentrated in high-risk Luminal B patients characterized by aggressive biology and high tumor burden. The gene discussed is ERBB2; the disease is neoplasm.